Reports Q2 revenue $43.2B, consensus $43.05B. “Second quarter results reflect the power of our diversified business and thoughtful execution of our strategic initiatives during a dynamic time for our industry, as we remain steadfast in our purpose to improve the health of humanity. We have prudently maintained our full-year outlook and are confident in the earnings power of our Health Benefits and Carelon businesses, which underpin our long-term targets,” said CEO Gail Boudreaux.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health price target raised to $620 from $600 at Truist
- Options Volatility and Implied Earnings Moves This Week, July 15 – July 19, 2024
- Elevance Health, Inc. (ELV) Q2 Earnings Cheat Sheet
- WSJ profiles issues with Elevance Health’s digital pharmacy
- Elevance Health initiated with an Overweight at Morgan Stanley